Breaking News
Get 50% Off 0
😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingPro CLAIM SALE
Close

Abbott Laboratories BDR (ABTT34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
48.32 +0.32    +0.67%
17:56:15 - Delayed Data. Currency in BRL ( Disclaimer )
  • Volume: 21
  • Bid/Ask: 48.30 / 48.47
  • Day's Range: 48.32 - 48.50
Type:  Equity
Market:  Brazil
ISIN:  BRABTTBDR007 
Abbott Laboratories BDR 48.32 +0.32 +0.67%

BVMF:ABTT34 Financials

 
This summary provides an overview of the most significant critical numbers from each of the Abbott Laboratories BDR financial reports, including theAbbott Laboratories BDR income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the BVMF:ABTT34 financials over time via breakdowns of their annual reports.

Abbott Laboratories reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 10,377 million compared to USD 9,978 million a year ago. Net income was USD 1,302 million compared to USD 1,375 million a year ago. Diluted earnings per share from continuing operations was USD 0.74 compared to USD 0.78 a year ago.For the six months, sales was USD 20,341 million compared to USD 19,725 million a year ago. Net income was USD 2,527 million compared to USD 2,693 million a year ago. Diluted earnings per share from continuing operations was USD 1.44 compared to USD 1.53 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ABTT34 Income Statement & Profits

Gross margin TTM 55.46%
Operating margin TTM 17.67%
Net Profit margin TTM 13.96%
Return on Investment TTM 11.65%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 10377 9964 10241 10143
Gross Profit 5807 5512 5710 5538
Operating Income 1681 1535 2057 1769
Net Income 1302 1225 1594 1436

ABTT34 Balance Sheet

Quick Ratio MRQ 0
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 37.89%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 72467 73214 72090
Total Liabilities 33424 34387 34396
Total Equity 39043 39043 38827 37694

ABTT34 Latest Cash Flow Statement

Cash Flow/Share TTM 4.11
Revenue/Share TTM 23.41
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1025 3038 1877
Cash From Investing Activities -425 -824 -634
Cash From Financing Activities -1176 -2052 -2340
Net Change in Cash -612 187 -1126
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ABTT34 Price Commentary

Write your thoughts about Abbott Laboratories BDR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email